Brian Cheng: Hey guys thanks for taking my call this morning. Gilmore, it looks like your collaboration with Bristol is going fairly well. I’m just curious if you can provide us some color on the collaboration. What were the factors that prompted, Bristol to open to more programs, any color on the next steps and how wide are the indications that the 10 programs are covering? Thank you.
Gilmore O’Neill: Thanks very much, Brian. We are actually very happy with the BMS collaboration. I think, one of the things that is driving opt-ins is that I believe that we have been providing very high-quality packages around the target nominations. The program or collaboration is focused on alpha based T-cells for the treatment of oncology and covers a rather broad sway of possibilities, which we haven’t actually disclosed publicly. But I think you can infer from the nature of the agreement, the target cell types and the oncology where there is likely to be. And I think more details will be forthcoming, as BMS advances the programs. Thanks Brian.
Brian Cheng: Thank you Gilmore.
Operator: Our next question is from Luca Issi with RBC Capital Markets. Please proceed.
Luca Issi: Great. Thanks so much for taking my question. Congrats on all the progress. I have two quick ones. Maybe circling back on a prior question based on if I may, I think you’ve spoken in the past about the RUBY trial potentially becoming registrational. Obviously you are now flagging that you’ll have 20 patients by year-end. How many patients and what is the minimum follow-up that you think is required to actually have a registrational package? Again, any color there will be much appreciated. And then maybe Gilmore for you on LCA-10 and IRD more broadly, can you just give us an update on what is a strategic option that you are exploring in the moment? What will be an ideal partner and ideal deal there? Thanks so much.
Baisong Mei: Thanks Luca, for your question. So just wanted to clarify. We have ambitious, but attainable goal to dose total of 20 patients by year-end. That is a separate from the registration of package. As Gilmore mentioned a bit earlier, that for the registrational package, a number of patients required and data package, we will need to actually have a engagement with the regulatory agency to finalize that.
Gilmore O’Neill: It is also worth adding that, the because we have actually agreement on the potency matrix or assay matrix that all the patients dosed in RUBY will actually provide data that will be part of marketing application. With regard to your second question and strategic options for our IRD divestiture, we are actually exploring potential divestitures. An ideal partner would be a sponsor interested in rare ocular diseases and potentially with a particular interest in AV delivery. But that is not a complete restriction, but an a key expertise in rare retinal disorders and their development would be an ideal partner for us. And we look forward to being able to update you in the future on the progress we make.
Luca Issi: Got you. Thanks so much.
Operator: Our next question is from Greg Harrison with Bank of America. Please proceed.
Greg Harrison: Hey, good morning. Thanks for taking the questions. First, just wanted to ask on expectations for the sickle cell data. I know it has been discussed previously, but just wanted to get your latest thoughts on, you know, what you need to show, to really have a competitive profile here in sickle cell. And then on another note, what else needs to happen with the reorganization and how close are you to be complete with that?
